ANTX - CIK 0001880438
The table below shows AN2 Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.07M | -$10.62M | -$17.59M | -$11.60M | -$6.74M | -$1.54M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $8.29M | $9.19M | $26.29M | $10.89M | $13.98M | - |
| Dividends paid | - | - | - | - | - |
AN2 Therapeutics, Inc. reported operating cash flow of -$29.83M for fiscal year 2025. That is up 39.4% from -$49.26M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$20.48M (FY 2021) to -$29.83M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $37.33M | $65.00K | $349.00K | $199.00K | $63.19M | $79.74M |